Buscar
Arrowhead Pharmaceuticals Inc
ARWRAñadir a la lista de seguimiento
84.650USD
-2.670-3.06%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
11.92BCap. mercado
PérdidaP/E TTM
Más Datos de Arrowhead Pharmaceuticals Inc Compañía
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Información de Arrowhead Pharmaceuticals Inc
Símbolo de cotizaciónARWR
Nombre de la empresaArrowhead Pharmaceuticals Inc
Fecha de salida a bolsaDec 14, 1993
Director ejecutivoAnzalone (Christopher Richard)
Número de empleados711
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 14
Dirección177 E Colorado Blvd
CiudadPASADENA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91105
Teléfono16266964702
Sitio Webhttps://arrowheadpharma.com/
Símbolo de cotizaciónARWR
Fecha de salida a bolsaDec 14, 1993
Director ejecutivoAnzalone (Christopher Richard)
Ejecutivos de Arrowhead Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-0.35%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+4.20%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
60.04K
-4.95%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+21.69%
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
35.72K
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
33.60K
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Lead Independent Director
Lead Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-0.35%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+4.20%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
60.04K
-4.95%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+21.69%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Arrowhead Pharmaceuticals Inc?
Los cinco principales accionistas de Arrowhead Pharmaceuticals Inc son: Dr. Christopher Richard (Chris) Anzalone, Ph.D.
¿Cuántas instituciones poseen acciones de Arrowhead Pharmaceuticals Inc (ARWR)?
A fecha de 2026Q1, 735 instituciones poseen acciones de Arrowhead Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 111.75M, lo que representa el 79.34% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -13922396.00.